Original Research
Accepted on 17 Nov 2025
Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a post-hoc analysis of a phase 3 trial
in Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders